RxDoctor Payments Data

Rodrigo Bolanos, MD

Cardiovascular Disease · Winter Haven, FLNPI 1962504456

Payments from drug & device makers

$98,279in general payments, 2019–2025

Across 395 payments — averaging $248.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$51K
  • Johnson & Johnson$18K
  • Biosense Webster, Inc.$16K
  • Boston Scientific$9K
  • Medtronic$3K
  • Elutia, Inc.$145
  • plus $628 from 13 others

What the payments were for

  • Consulting fees$62,42569%
  • Speaking & faculty fees$16,81519%
  • Travel & lodging$3,4764%
  • Food & beverage$8,0289%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,279 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$246,087
Medicare patients
930
Services billed
3,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban511$503,348
XareltoRivaroxaban122$131,283
Diltiazem 12hr ErDiltiazem Hcl94$16,238
Dofetilide83$14,702
CorlanorIvabradine Hcl12$9,868
SotalolSotalol Hcl574$8,640
Flecainide Acetate215$7,143
Metoprolol Succinate621$6,632
Dabigatran EtexilateDabigatran Etexilate Mesylate18$5,405
Amiodarone Hcl362$3,848
Diltiazem Hcl100$2,008
Mexiletine Hcl19$1,547
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$683
Carvedilol67$513
ClopidogrelClopidogrel Bisulfate19$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$18,101$131,283122 claims
AmgenCorlanor$29$9,86812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Winter Haven

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →